is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.
Click for full image >>
TG Therapeutics Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101 (ublituximab) Monotherapy in the British Journal of Haematology
TG Therapeutics to Present at the 2017 BIO CEO & Investor Conference
2 Gansevoort Street, 9th Floor, New York NY 10014 - P:212.554.4484 - Email Us
Web Site Development by Tidal Media Group